Australia markets open in 8 hours 49 minutes

Cerevel Therapeutics Holdings, Inc. (CERE)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
41.97+0.38 (+0.90%)
As of 11:11AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 7.55B
Enterprise value 6.93B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)11.21
Enterprise value/revenue N/A
Enterprise value/EBITDA -16.66

Trading information

Stock price history

Beta (5Y monthly) 1.49
52-week change 358.48%
S&P500 52-week change 321.61%
52-week high 343.59
52-week low 319.59
50-day moving average 341.92
200-day moving average 332.48

Share statistics

Avg vol (3-month) 31.43M
Avg vol (10-day) 31.22M
Shares outstanding 5181.58M
Implied shares outstanding 6183.47M
Float 877.23M
% held by insiders 115.32%
% held by institutions 186.57%
Shares short (28 Mar 2024) 49.62M
Short ratio (28 Mar 2024) 47.56
Short % of float (28 Mar 2024) 411.15%
Short % of shares outstanding (28 Mar 2024) 45.30%
Shares short (prior month 29 Feb 2024) 47.1M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-24.73%
Return on equity (ttm)-72.44%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -441.64M
Net income avi to common (ttm)-432.84M
Diluted EPS (ttm)-2.67
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)990.96M
Total cash per share (mrq)5.46
Total debt (mrq)480.78M
Total debt/equity (mrq)71.36%
Current ratio (mrq)10.92
Book value per share (mrq)3.71

Cash flow statement

Operating cash flow (ttm)-342.3M
Levered free cash flow (ttm)-198.16M